Giuseppe
Emeritus
Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine (PNAS, abstract, edited)
[Source: Proc Natl Acad Sci USA, full text: <cite cite="http://www.pnas.org/content/108/3/1140.short?rss=1">Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine ? PNAS</cite>. Abstract, edited.]
Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine
1. Grace L. Chen a,1, 2. Yuk-Fai Lau a,b,1, 3. Elaine W. Lamirande a, 4. Amber W. McCall a, and 5. Kanta Subbarao a,2
Author Affiliations
1. a Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892; and
2. b Medical Countermeasures (Biological) Laboratory, Defence Medical and Environmental Research Institute, DSO National Laboratories, Republic of Singapore 117510
1. Edited by Peter Palese, Mount Sinai School of Medicine, New York, NY, and approved December 6, 2010 (received for review July 19, 2010)
2. ↵1G.L.C. and Y.-F.L. contributed equally to this work.
Abstract
The robust immune response to a single dose of pandemic 2009 H1N1 vaccine suggests that a large segment of the population has been previously primed. We evaluated the effect of seasonal (s) H1N1 infection, s-trivalent inactivated vaccine (s-TIV), and trivalent s-live attenuated influenza vaccine (s-LAIV) before immunization with a pandemic live attenuated influenza vaccine (p-LAIV) in mice. We compared serum and mucosal antibody and pulmonary CD8 and CD4 responses and the virologic response to challenge with a wild-type 2009 pandemic H1N1 (p-H1N1) virus. Two doses of p-LAIV induced cellular immune and robust ELISA and neutralizing antibody responses that were associated with complete protection from p-H1N1 challenge. A single dose of p-LAIV induced a cellular response and ELISA but not a neutralizing antibody response, and incomplete protection from p-H1N1 virus challenge. Primary infection with s-H1N1 influenza virus followed by a dose of p-LAIV resulted in cross-reactive ELISA antibodies and a robust cellular immune response that was also associated with complete protection from p-H1N1 virus challenge. A lower-magnitude but similar response associated with partial protection was seen in mice that received a dose of s-LAIV followed by p-LAIV. Mice that received a dose of s-TIV followed by p-LAIV did not show any evidence of priming. In summary, prior infection with a seasonal influenza virus or s-LAIV primed mice for a robust response to a single dose of p-LAIV that was associated with protection equivalent to two doses of the matched pandemic vaccine.
Footnotes
* 2 To whom correspondence should be addressed. E-mail: ksubbarao@niaid.nih.gov.
* Author contributions: G.L.C., Y.-F.L., and K.S. designed research; G.L.C., Y.-F.L., E.W.L., and A.W.M. performed research; G.L.C. and Y.-F.L. analyzed data; and G.L.C., Y.-F.L., E.W.L., A.W.M., and K.S. wrote the paper.
* The authors declare no conflict of interest.
* This article is a PNAS Direct Submission.
* This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1009908108/-/DCSupplemental.
-
------
[Source: Proc Natl Acad Sci USA, full text: <cite cite="http://www.pnas.org/content/108/3/1140.short?rss=1">Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine ? PNAS</cite>. Abstract, edited.]
Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine
1. Grace L. Chen a,1, 2. Yuk-Fai Lau a,b,1, 3. Elaine W. Lamirande a, 4. Amber W. McCall a, and 5. Kanta Subbarao a,2
Author Affiliations
1. a Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892; and
2. b Medical Countermeasures (Biological) Laboratory, Defence Medical and Environmental Research Institute, DSO National Laboratories, Republic of Singapore 117510
1. Edited by Peter Palese, Mount Sinai School of Medicine, New York, NY, and approved December 6, 2010 (received for review July 19, 2010)
2. ↵1G.L.C. and Y.-F.L. contributed equally to this work.
Abstract
The robust immune response to a single dose of pandemic 2009 H1N1 vaccine suggests that a large segment of the population has been previously primed. We evaluated the effect of seasonal (s) H1N1 infection, s-trivalent inactivated vaccine (s-TIV), and trivalent s-live attenuated influenza vaccine (s-LAIV) before immunization with a pandemic live attenuated influenza vaccine (p-LAIV) in mice. We compared serum and mucosal antibody and pulmonary CD8 and CD4 responses and the virologic response to challenge with a wild-type 2009 pandemic H1N1 (p-H1N1) virus. Two doses of p-LAIV induced cellular immune and robust ELISA and neutralizing antibody responses that were associated with complete protection from p-H1N1 challenge. A single dose of p-LAIV induced a cellular response and ELISA but not a neutralizing antibody response, and incomplete protection from p-H1N1 virus challenge. Primary infection with s-H1N1 influenza virus followed by a dose of p-LAIV resulted in cross-reactive ELISA antibodies and a robust cellular immune response that was also associated with complete protection from p-H1N1 virus challenge. A lower-magnitude but similar response associated with partial protection was seen in mice that received a dose of s-LAIV followed by p-LAIV. Mice that received a dose of s-TIV followed by p-LAIV did not show any evidence of priming. In summary, prior infection with a seasonal influenza virus or s-LAIV primed mice for a robust response to a single dose of p-LAIV that was associated with protection equivalent to two doses of the matched pandemic vaccine.
Footnotes
* 2 To whom correspondence should be addressed. E-mail: ksubbarao@niaid.nih.gov.
* Author contributions: G.L.C., Y.-F.L., and K.S. designed research; G.L.C., Y.-F.L., E.W.L., and A.W.M. performed research; G.L.C. and Y.-F.L. analyzed data; and G.L.C., Y.-F.L., E.W.L., A.W.M., and K.S. wrote the paper.
* The authors declare no conflict of interest.
* This article is a PNAS Direct Submission.
* This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1009908108/-/DCSupplemental.
-
------